Literature DB >> 25958848

The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis.

Xiao-Dong Jing1, Xiao-Ming Wei1, Song-Bai Deng1, Jian-Lin Du1, Ya-Jie Liu1, Qiang She2.   

Abstract

BACKGROUND: High-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) contributed to several beneficial effects in the cardiovascular system. We explored the relationship between the HDL-S1P concentrations and coronary in-stent restenosis (ISR).
METHODS: Fifty consecutive patients with ISR and 50 normal control subjects were included. The serum S1P, HDL-S1P and clinical data were collected to explore the relationships between these parameters and ISR.
RESULTS: The patients with ISR had significantly lower concentrations of serum S1P (96.10 ± 26.33 vs. 113.40 ± 32.72; P = 0.004) and HDL-S1P (32.81 ± 10.02 vs. 42.72 ± 11.75; P < 0.001). All included patients were divided into four quartiles based on their concentrations of HDL-S1P: Quartile 1 (18.63-28.51 ng/ml), Quartile 2 (28.62-37.28 ng/ml), Quartile 3 (37.35-45.27 ng/ml), and Quartile 4 (45.59-79.36 ng/ml). The rates of ISR were 84%, 48%, 40% and 28%, respectively. The patients in Quartile 1 exhibited significantly higher rates of ISR compared with the other groups (P = 0.001). A multivariate stepwise logistic regression analysis indicated that HDL-S1P (OR = 0.846, 95% CI = 0.767-0.932, P = 0.001) was an independent predictor of ISR. An ROC analysis indicated that HDL-S1P = 30.37 ng/ml and had a 90% sensitivity and a 52% specificity in predicting ISR.
CONCLUSIONS: HDL-S1P is an independent predictor of ISR, and patients with higher concentrations of HDL-S1P have a low risk of ISR.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  High-density lipoprotein; In-stent restenosis; Inflammation; Sphingosine-1-phosphate

Mesh:

Substances:

Year:  2015        PMID: 25958848     DOI: 10.1016/j.cca.2015.04.038

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  10 in total

1.  HDL and Lipid Metabolism.

Authors:  Qi Zhang; Yilang Ke; Huashan Hong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis.

Authors:  Linda Sasset; Yi Zhang; Teresa M Dunn; Annarita Di Lorenzo
Journal:  Trends Endocrinol Metab       Date:  2016-08-22       Impact factor: 12.015

Review 3.  Lysolipids in Vascular Development, Biology, and Disease.

Authors:  Eric Engelbrecht; Calum A MacRae; Timothy Hla
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-17       Impact factor: 8.311

Review 4.  Pharmacological Intervention to Modulate HDL: What Do We Target?

Authors:  Nicholas J Woudberg; Sarah Pedretti; Sandrine Lecour; Rainer Schulz; Nicolas Vuilleumier; Richard W James; Miguel A Frias
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

Review 5.  Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases.

Authors:  Elena M G Diarte-Añazco; Karen Alejandra Méndez-Lara; Antonio Pérez; Núria Alonso; Francisco Blanco-Vaca; Josep Julve
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

6.  Sphingosine-1-Phosphate Receptor 1 Regulates Cardiac Function by Modulating Ca2+ Sensitivity and Na+/H+ Exchange and Mediates Protection by Ischemic Preconditioning.

Authors:  Petra Keul; Marcel M G J van Borren; Alexander Ghanem; Frank Ulrich Müller; Antonius Baartscheer; Arie O Verkerk; Frank Stümpel; Jan Sebastian Schulte; Nazha Hamdani; Wolfgang A Linke; Pieter van Loenen; Marek Matus; Wilhelm Schmitz; Jörg Stypmann; Klaus Tiemann; Jan-Hindrik Ravesloot; Astrid E Alewijnse; Sven Hermann; Léon J A Spijkers; Karl-Heinz Hiller; Deron Herr; Gerd Heusch; Michael Schäfers; Stephan L M Peters; Jerold Chun; Bodo Levkau
Journal:  J Am Heart Assoc       Date:  2016-05-20       Impact factor: 5.501

Review 7.  HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications.

Authors:  Bodo Levkau
Journal:  Front Pharmacol       Date:  2015-10-20       Impact factor: 5.810

8.  Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis.

Authors:  Hyung Joon Joo; Han Saem Jeong; Hyungdon Kook; Seung Hun Lee; Jae Hyoung Park; Soon Jun Hong; Cheol Woong Yu; Do-Sum Lim
Journal:  BMC Cardiovasc Disord       Date:  2018-06-11       Impact factor: 2.298

Review 9.  Fetal High-Density Lipoproteins: Current Knowledge on Particle Metabolism, Composition and Function in Health and Disease.

Authors:  Julia T Stadler; Christian Wadsack; Gunther Marsche
Journal:  Biomedicines       Date:  2021-03-30

10.  First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.

Authors:  Luc Bergougnan; Sara Armani; Georg Golor; Agnes Tardat; Olivier Vitse; Fabrice Hurbin; Michel Scemama; Franck Poitiers; David Radzik; Christophe Gaudin; Lionel Hovsepian; Anthony J Muslin; Stephane Kirkesseli; Paul Deutsch; Ashfaq A Parkar
Journal:  Br J Clin Pharmacol       Date:  2020-07-08       Impact factor: 3.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.